HCA Healthcare reported that three of its hospitals were named among America’s 50 Best Hospitals for 2026 and 15 were included among America’s 100 Best Hospitals by Healthgrades. In total, 44 HCA facilities earned spots on the Healthgrades America’s 250 Best Hospitals list, reflecting top-quartile performance in survival rates, complications, and patient experience metrics. These accolades underscore HCA’s investment in clinical protocols, technology adoption and standardized care pathways, reinforcing its reputation for quality outcomes in areas such as cardiac surgery, orthopedics and maternity care.

In the fourth quarter of fiscal 2025, HCA delivered adjusted earnings per share that rose by 28.8% year-over-year to $8.01, driven by strong patient volumes and an increase in revenue per equivalent admission of 2.9%. Same-facility admissions grew 2.4%, while equivalent admissions climbed 2.5%, reflecting broader utilization of outpatient and ancillary services. Revenue increased by 6.7% year-over-year to $19.51 billion, and adjusted EBITDA expanded 10.8% to $4.11 billion, lifting the margin to 21.1% from 20.3% a year earlier.

Building on robust cash flow generation, HCA announced a new $10 billion share repurchase authorization, representing roughly 10% of its market capitalization. The company has already retired a significant portion of its outstanding shares over the past year, contributing to a greater than 40% total return for shareholders over that period. Margin expansion, fueled by cost controls and leverage on fixed costs, has supported free cash flow yield of approximately 6%, enabling further capital return without compromising strategic investments in facility upgrades and digital health initiatives.

For fiscal 2026, HCA projects adjusted earnings per share in a range of $29.10 to $31.50 and revenue between $76.5 billion and $80 billion, both figures exceeding consensus expectations. Management cited ongoing pricing momentum and admissions growth as key drivers, while signaling that incremental margin benefits may moderate as labor and regulatory costs rise. Potential headwinds include changes to Medicaid reimbursement and Affordable Care Act subsidies. At current valuation of around 16 times earnings, analysts note that policy shifts and margin pressure risks are not fully reflected in share prices.